Catalyst Pharmaceuticals Inc. (CPRX)

2.51
NASDAQ : Health Technology
Prev Close 2.54
Day Low/High 2.46 / 2.56
52 Wk Low/High 1.62 / 4.51
Avg Volume 657.70K
Exchange NASDAQ
Shares Outstanding 102.47M
Market Cap 260.28M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Commit To Buy Catalyst Pharmaceuticals At $2.50, Earn 13.8% Annualized Using Options

Commit To Buy Catalyst Pharmaceuticals At $2.50, Earn 13.8% Annualized Using Options

Investors eyeing a purchase of Catalyst Pharmaceuticals Inc shares, but tentative about paying the going market price of $3.28/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $2.50 strike, which has a bid at the time of this writing of 20 cents.

Alkermes Jumps on License Deal With Biogen -- Biotech Movers

Alkermes Jumps on License Deal With Biogen -- Biotech Movers

Alkermes and Biogen have inked a pact to develop and commercialize ALKS 8700, which is in Phase 3 development for treating relapsing forms of multiple sclerosis.

First Week of January 2018 Options Trading For Catalyst Pharmaceuticals (CPRX)

First Week of January 2018 Options Trading For Catalyst Pharmaceuticals (CPRX)

Investors in Catalyst Pharmaceuticals Inc saw new options begin trading this week, for the January 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CPRX options chain for the new January 2018 contracts and identified one put and one call contract of particular interest.

Catalyst Pharmaceuticals Announces Third Quarter 2017 Financial Results And Provides Corporate Update

Catalyst Pharmaceuticals Announces Third Quarter 2017 Financial Results And Provides Corporate Update

Company to Host Quarterly Conference Call at 8:30 am EDT Tomorrow

First Week Of CPRX June 2018 Options Trading

First Week Of CPRX June 2018 Options Trading

Investors in Catalyst Pharmaceuticals Inc saw new options begin trading this week, for the June 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

First Week of November 17th Options Trading For Catalyst Pharmaceuticals (CPRX)

First Week of November 17th Options Trading For Catalyst Pharmaceuticals (CPRX)

Investors in Catalyst Pharmaceuticals Inc saw new options begin trading this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CPRX options chain for the new November 17th contracts and identified the following put contract of particular interest.

Short Interest In Catalyst Pharmaceuticals Declines 35.4%

Short Interest In Catalyst Pharmaceuticals Declines 35.4%

The most recent short interest data has been released for the 09/15/2017 settlement date, which shows a 2,312,447 share decrease in total short interest for Catalyst Pharmaceuticals Inc , to 4,220,460, a decrease of 35.40% since 08/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Catalyst Pharmaceuticals Announces Second Quarter 2017 Financial Results And Provides Corporate Update

Catalyst Pharmaceuticals Announces Second Quarter 2017 Financial Results And Provides Corporate Update

Company to Host Quarterly Conference Call at 8:30 am EDT Tomorrow

March 2018 Options Now Available For Catalyst Pharmaceuticals (CPRX)

March 2018 Options Now Available For Catalyst Pharmaceuticals (CPRX)

Investors in Catalyst Pharmaceuticals Inc saw new options begin trading today, for the March 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Commit To Purchase Catalyst Pharmaceuticals At $2.50, Earn 73% Annualized Using Options

Commit To Purchase Catalyst Pharmaceuticals At $2.50, Earn 73% Annualized Using Options

Investors eyeing a purchase of Catalyst Pharmaceuticals Inc shares, but cautious about paying the going market price of $3.04/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the July put at the $2.50 strike, which has a bid at the time of this writing of 5 cents.